Update in treatment options for psoriatic arthritis

Expert Review of Clinical Immunology

Volumn 5, Issue 6, 2009, Pages 779-788

  De Vlam, Kurt ^a   Lories, Rik J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biologicals; Psoriatic arthritis; Remission; TNF blocking agents

Indexed keywords

CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

DISABILITY; ENTHESITIS; HUMAN; JOINT DESTRUCTION; PSORIATIC ARTHRITIS; REVIEW;

EID: 77949802540     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.49     Document Type: Review

References (67)

1. Zink A, Thiele K, Huscher D et al.; German Collaborative Arthritis Centres. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 33(1), 86-90 (2006).
2. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: Multivariate relative risk model. J. Rheumatol. 22(4), 675-679 (1995).
3. Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J. Rheumatol. 28(5), 1045-1048 (2001).
4. Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J. Rheumatol. 30(5), 1022-1026 (2003).
5. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54(8), 2665-2673 (2006).
6. Clegg DO, Reda DJ, Mejias E et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 39(12), 2013-2020 (1996).
7. Kaltwasser JP, Nash P, Gladman D et al.; Treatment of Psoriatic Arthritis study group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 50(6), 1939-1950 (2004).
8. Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J. Cutan. Med. Surg. 11(2), 57-66 (2007).
9. Durrani K, Foster CS. Psoriatic uveitis: A distinct clinical entity? Am. J. Ophthalmol. 139(1), 106-111 (2005).
10. Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep. 8(5), 355-363 (2006).
11. Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J. Rheumatol. 33(2), 210-212 (2006).
12. Zenz R, Eferl R, Kenner L et al. Psoriasislike skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 15, 437(7057), 369-375 (2005).
13. de Vlam K, Lories RJ. Remission in psoriatic arthritis. Curr. Rheumatol. Rep. 10(4), 297-302 (2008).
14. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann. Rheum. Dis. (2009).) (Epub ahead of print).
15. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin. Exp. Rheumatol. 24(6 Suppl. 43), S83-S87 (2006
16. Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin. Arthritis Rheum. 37(3), 164-173 (2007).
17. Scarpa R, Peluso R, Atteno M et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin. Rheumatol. 27(7), 823-826 (2008).
18. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort. J. Rheumatol. 35(3), 469-471 (2008).
19. Kaltwasser JP. Leflunomide in psoriatic arthritis. Autoimmun. Rev. 6(8), 511-514 (2007).
20. Malesci D, Tirri R, Buono R, LaMontagna G. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin. Exp. Rheumatol. 25(6), 881-884 (2007).
21. Fraser AD, van Kuijk AW, Westhovens R et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann. Rheum. Dis. 64(6), 859-864 (2005).
22. Cantini F, Niccoli L, Nannini C et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 47(6), 872-876 (2008).
23. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357(9271), 1842-1847 (2001).
24. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227), 385-390 (2000).
25. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55(4), 598-606 (2006).
26. Antoni C, Krueger GG, de Vlam K et al.; IMPACT 2 trial investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum Dis. 64(8), 1150-1157 (2005).
27. Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 56(2), 476-488 (2007).
28. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52(4), 1227-1236 (2005).
29. Kavanaugh A, Antoni CE, Gladman D et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann. Rheum. Dis. 65(8), 1038-1043 (2006).
30. Antoni CE, Kavanaugh A, van der Heijde D et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J. Rheumatol. 35(5), 869-876 (2008).
31. Kavanaugh A, Krueger GG, Beutler A et al.; IMPACT 2 study group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann. Rheum. Dis. 66(4), 498-505 (2007).
32. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50(7), 2264-2272 (2004).
33. Genovese MC, Mease PJ, Thomson GT; M02-570 study group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J. Rheumatol. 34(5), 1040-1050 (2007).
34. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60(4), 976-986 (2009).
35. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Med.ich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: Patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann. Rheum. Dis. 66(2), 163-168 (2007).
36. Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis. 68(5), 702-709 (2009)
37. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the south Swedish Arthritis Treatment Group register. Ann. Rheum. Dis. 67(3), 364-369 (2008).
38. Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann. Rheum. Dis. 67(11), 1650-1651 (2008).
39. de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 45(3), 321-324 (2006).
40. Conti F, Ceccarelli F, Marocchi E et al. Switching tumour necrosis factor a antagonists in patients with ankylosing spondylitis and psoriatic arthritis: An observational study over a 5-year period. Ann. Rheum Dis. 66(10), 1393-1397 (2007
41. Coates LC, Cawkwell LS, Ng NW et al. Sustained response to long-term biologics and switching in psoriatic arthritis: Results from real life experience. Ann. Rheum. Dis. 67(5), 717-719 (2008).
42. Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198(12), 1951-1957 (2003).
43. Krueger GG, Langley RG, Leonardi C et al.; CNTO (1275) Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356(6), 580-592 (2007).
44. Leonardi CL, Kimball AB, Papp KA et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625), 1665-1674 (2008).
45. Papp KA, Langley RG, Lebwohl M et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625), 1675-1684 (2008).
46. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664), 633-640 (2009)
47. Gladman DD, Inman RD, Cook RJ et al. International spondyloarthritis interobserver reliability exercise - the INSPIRE study: I. Assessment of spinal measures. J. Rheumatol. 34(8), 1733-1739 (2007).
48. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J. Rheumatology 32(9), 1745-1750 (2005).
49. DAgostino MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum. 46(3), 840-841 (2002).
50. DAgostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: sA crosssectional study. Arthritis Rheum. 48(2), 523-533 (2003).
51. Marzo-Ortega H, McGonagle D, Rhodes LA et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann. Rheum. Dis. 66(6), 778-781 (2007).
52. Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst. Rev. 2, CD004524 (2004).
53. Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J. Rheumatol. 27(3), 714-718 (2000).
54. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin. Exp. Rheumatol. 13(5), 589-593 (1995).
55. Wollina U, Ständer K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - short- and long-term toxicity in 104 patients. Clin. Rheumatol. 20(6), 406-410 (2001).
56. Whiting-OKeefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. 90(6), 711-716 (1991)
57. Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: A 10-year follow-up. Br. J. Dermatol. 144(1), 100-103 (2001).
58. Sund S, Førre O, Berg KJ, Kvien TK, Hovig T. Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin. Nephrol. 41(1), 33-40 (1994).
59. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum Dis. 67(6), 855-859 (2008).
60. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J. Rheumatol. 35(5), 883-890 (2008).
61. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: A clinic experience. J. Rheumatol. 25(10), 1957-1961 (1998).
62. Macchioni P, Boiardi L, Cremonesi T et al. The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol. Int. 18(1), 27-33 (1998)
63. Mease PJ, Kivitz AJ, Burch FX et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J. Rheumatol. 33(4), 712-721 (2006).
64. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis. 68(9), 1387-1394 (2008).
65. de Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J. Rheumatol. 35(7), 1443-1448 (2008).
66. Lories RJ, Derese I, Luyten FP, de Vlam K. Activation of nuclear factor k B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin. Exp. Rheumatol. 26(1), 96-102 (2008).
67. Wassenberg S, Fischer-Kahle V, Herborn G, Rau R. A method to score radiographic change in psoriatic arthritis. Z. Rheumatol. 60(3), 156-166 (2001).